{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:51Z","timestamp":1760060211100,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Triclabendazole (TCBZ) is the gold standard treatment for fascioliasis. However, reports on resistance are increasing, emphasizing the need for alternative therapy. Combining TCBZ with ivermectin (IVM) was found to be effective for treating animal fascioliasis. Building on this, we aimed to evaluate the efficacy of the TCBZ\/IVM combination therapy for human fascioliasis. This study enrolled 136 patients with Fasciola from Upper Egypt, and they were divided into the first group (n = 65), who received TCBZ monotherapy, and the second group (n = 71), who received the TCBZ\/IVM combination. Assessments were to evaluate treatment response based on clinical, eosinophilic, and radiological parameters. Chronic fasciolosis was diagnosed in 17 patients (12.5%). No differences were observed in age and sex. Significant improvements were noted in all parameters in both groups, with more pronounced effects observed in the second group. A significantly higher complete response, including clinical, eosinophilic, and radiological improvements, was reported in the combined therapy group, with 53.3% compared to 26.2% in the monotherapy group (p &lt; 0.001). A high baseline eosinophilic count was significantly associated with response. The efficacy of the TCBZ\/IVM combination for treating human fascioliasis suggested a possible boosting effect, which can benefit regions of TCBZ failure. Further large-scale randomized studies are warranted to confirm these findings.<\/jats:p>","DOI":"10.3390\/tropicalmed10080221","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:45:11Z","timestamp":1754466311000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Efficacy of Triclabendazole\/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-1715","authenticated-orcid":false,"given":"Waleed Attia","family":"Hassan","sequence":"first","affiliation":[{"name":"Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-3985","authenticated-orcid":false,"given":"Haidi Karam-Allah","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1735-0168","authenticated-orcid":false,"given":"Mona","family":"Gaber","sequence":"additional","affiliation":[{"name":"Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5811-7592","authenticated-orcid":false,"given":"Samia S.","family":"Alkhalil","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh 11961, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2947-3122","authenticated-orcid":false,"given":"Alzahraa Abdelraouf","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.idc.2012.03.008","article-title":"Trematode infections: Liver and lung flukes","volume":"26","author":"Duthaler","year":"2012","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_2","unstructured":"PAHO (2024). Operational Guidelines for the Elimination of Human Fascioliasis as a Public Health Problem in the Americas, World Health Organization. Pan American Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789275128084."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eimc.2020.01.014","article-title":"Human fascioliasis emergence risks in developed countries: From individual patients and small epidemics to climate and global change impacts","volume":"38","year":"2020","journal-title":"Enferm. Infecc. Microbiol. Clin. (Engl. Ed.)"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mas-Coma, S., Valero, M.A., and Bargues, M.D. (2019). Fascioliasis. Digenetic Trematodes., 71\u2013103.","DOI":"10.1007\/978-3-030-18616-6_4"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0304-4017(01)00613-6","article-title":"Identification of the Egyptian species of Fasciola","volume":"103","author":"Lotfy","year":"2002","journal-title":"Vet. Parasitol."},{"key":"ref_6","first-page":"142","article-title":"Prevalence and phylogenetic analysis of Fasciola species in upper Egypt based on ribosomal ITS-2 gene sequencing","volume":"16","author":"Khalafala","year":"2020","journal-title":"Egyp. Vet. Med. Soc. Parasitol. J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ramadan, H.K.-A., Hassan, W.A., Elossily, N.A., Ahmad, A.A., Mohamed, A.A., Abd-Elkader, A.S., Abdelsalam, E.M.N., and Khojah, H.M. (2019). Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt. PLoS Neglected Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007779"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ahmad, A.A., Ramadan, H.K.-A., Hassan, W.A., Hakami, M.A., Huseein, E.A.M., Mohamed, S.A.-A., Mohamed, A.A., and Elossily, N.A. (2022). New perspectives for fascioliasis in Upper Egypt\u2019s new endemic region: Sociodemographic characteristics and phylogenetic analysis of Fasciola in humans, animals, and lymnaeid vectors. PLoS Neglected Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0011000"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Periago, M.V., Valero, M.A., Artigas, P., Agramunt, V.H., Bargues, M.D., Curtale, F., and Mas-Coma, S. (2021). Very high fascioliasis intensities in schoolchildren from Nile Delta Governorates, Egypt: The Old World highest burdens found in lowlands. J. Pathog., 10.","DOI":"10.3390\/pathogens10091210"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40794-024-00234-z","article-title":"Significance of climate change in the emergence of human fascioliasis in Upper Egypt","volume":"10","author":"Zanaty","year":"2024","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_11","unstructured":"WHO (2007). Report of the WHO Informal Meeting on Use of Triclabendazole in Fascioliasis Control: WHO Headquarters, Geneva, Switzerland 17\u201318 October 2006, World Health Organization."},{"key":"ref_12","first-page":"42","article-title":"Human fascioliasis: Prevalence and treatment in a rural area of Peru","volume":"2","author":"Ortiz","year":"2000","journal-title":"Infect. Dis. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3201\/eid1806.120302","article-title":"Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands","volume":"18","author":"Winkelhagen","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cabada, M.M., Lopez, M., Cruz, M., Delgado, J.R., Hill, V., and White, A.C. (2016). Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: A case series. PLoS Neglected Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004361"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.pt.2016.03.002","article-title":"Current threat of triclabendazole resistance in Fasciola hepatica","volume":"32","author":"Kelley","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, \u2018wonder drug\u2019 from Japan: The human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin\u2013old drug, new tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115838","DOI":"10.1016\/j.ejmech.2023.115838","article-title":"Antiparasitic activity of ivermectin: Four decades of research into a \u201cwonder drug\u201d","volume":"261","author":"Sulik","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","first-page":"317","article-title":"The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1017\/S0031182021001153","article-title":"Assessment of anthelmintic effectiveness to control Fasciola hepatica and paramphistome mixed infection in cattle in the humid tropics of Mexico","volume":"148","year":"2021","journal-title":"Parasitology"},{"key":"ref_21","first-page":"39","article-title":"Drug resistance in liver flukes","volume":"12","author":"Fairweather","year":"2020","journal-title":"Int. J. Parasitol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.vetpar.2011.11.030","article-title":"The role of combination anthelmintic formulations in the sustainable control of sheep nematodes","volume":"186","author":"Bartram","year":"2012","journal-title":"Vet. Parasitol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vetpar.2015.07.015","article-title":"Basic and clinical pharmacology contribution to extend anthelmintic molecules lifespan","volume":"212","author":"Lanusse","year":"2015","journal-title":"Vet. Parasitol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1645\/14-703.1","article-title":"Anthelmintic drug discovery: Into the future","volume":"101","author":"Geary","year":"2015","journal-title":"J. Parasitol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107363","DOI":"10.1016\/j.actatropica.2024.107363","article-title":"Ovicidal activity of diaryl dichalcogenides and ivermectin on Fasciola hepatica: A novel candidate for a blending-based therapeutic strategy","volume":"258","author":"Zugman","year":"2024","journal-title":"Acta Trop."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1751-0813.2002.tb11303.x","article-title":"The efficacy of formulations of triclabendazole and ivermectin in combination against liver fluke (Fasciola hepatica) and gastro-intestinal nematodes in cattle and sheep and sucking lice species in cattle","volume":"80","author":"Stevenson","year":"2002","journal-title":"Aust. Vet. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vetpar.2006.06.025","article-title":"The effect of a parenteral ivermectin\/closantel injection on the growth and reproductive development of early immature Fasciola hepatica in cattle","volume":"142","author":"Hanna","year":"2006","journal-title":"Vet. Parasitol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ijpara.2004.04.010","article-title":"An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis","volume":"34","author":"Yates","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/QCO.0b013e328010774c","article-title":"Ivermectin: Uses and impact 20 years on","volume":"19","author":"Fox","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0169-4758(95)80117-0","article-title":"Worm control and anthelmintic resistance: Adventures with a model","volume":"11","author":"Barnes","year":"1995","journal-title":"Parasitol. Today"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1645\/GE-922R.1","article-title":"Resistance-induced changes in triclabendazole transport in Fasciola hepatica: Ivermectin reversal effect","volume":"92","author":"Mottier","year":"2006","journal-title":"J. Parasitol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00320","DOI":"10.1016\/j.parepi.2023.e00320","article-title":"Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru","volume":"23","year":"2023","journal-title":"Parasite Epidemiol. Control"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4269\/ajtmh.2008.78.388","article-title":"A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam","volume":"78","author":"Hien","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_34","first-page":"149","article-title":"Human fascioliasis: Current epidemiological status and strategies for diagnosis, treatment, and control","volume":"11","author":"Caravedo","year":"2020","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_35","unstructured":"WHO (2025, July 20). Bench Aids for the Diagnosis of Intestinal Parasites. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241515344."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41594-024-01298-3","article-title":"Target-based discovery of a broad-spectrum flukicide","volume":"31","author":"Sprague","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3201\/eid2707.203900","article-title":"Triclabendazole treatment failure for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru","volume":"27","author":"Morales","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/tropej\/49.5.264","article-title":"Distribution of human fascioliasis by age and gender among rural population in the Nile Delta, Egypt","volume":"49","author":"Curtale","year":"2003","journal-title":"J. Trop. Pediatr."},{"key":"ref_39","first-page":"5","article-title":"Clinical signs and household characteristics associated with human fascioliasis among rural population in Egypt: A case-control study","volume":"45","author":"Curtale","year":"2003","journal-title":"Parassitologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.trstmh.2006.05.006","article-title":"Human fascioliasis infection: Gender differences within school-age children from endemic areas of the Nile Delta, Egypt","volume":"101","author":"Curtale","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-308X(09)69002-3","article-title":"Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control","volume":"69","author":"Valero","year":"2009","journal-title":"Adv. Parasitol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ibrahim, N., Abdel Khalek, E.M., Makhlouf, N.A., Abdel-Gawad, M., Mekky, M., Ramadan, H.K.-A., Abu-Elfatth, A., El-Latif, N.A., Hassan, M.K., and Eldeeb, R. (2023). Clinical characteristics of human fascioliasis in Egypt. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-42957-7"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/trstmh\/trz093","article-title":"Triclabendazole in the treatment of human fascioliasis: A review","volume":"113","author":"Gandhi","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1517\/13543784.14.12.1513","article-title":"Triclabendazole for the treatment of fascioliasis and paragonimiasis","volume":"14","author":"Keiser","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108830","DOI":"10.1016\/j.exppara.2024.108830","article-title":"Fosfatriclaben: Effective dose determination and comparative efficacy assessment with closantel, triclabendazole+ ivermectin, triclabendazole+ albendazole in artificially infected cattle","volume":"266","author":"Castillo","year":"2024","journal-title":"Exp. Parasitol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jgar.2021.03.023","article-title":"Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens","volume":"25","author":"Terashima","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.26719\/1999.5.5.888","article-title":"human fascioliasis: A community-based study","volume":"5","author":"Farghaly","year":"1999","journal-title":"East. Mediterr. Health J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1440-1681.2004.04093.x","article-title":"Randomized trial of a single, double and triple dose of 10 mg\/kg of a human formulation of triclabendazole in patients with fascioliasis","volume":"31","author":"Talaie","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.26719\/2011.17.4.266","article-title":"Evaluation of two doses of triclabendazole in treatment of patients with combined schistosomiasis and fascioliasis","volume":"17","author":"Osman","year":"2011","journal-title":"East. Mediterr. Health J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.vetpar.2009.03.032","article-title":"Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle","volume":"162","author":"Hutchinson","year":"2009","journal-title":"Vet. Parasitol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tvjl.2008.06.001","article-title":"Combined use of ivermectin and triclabendazole in sheep: In vitro and in vivo characterisation of their pharmacological interaction","volume":"182","author":"Lifschitz","year":"2009","journal-title":"Vet. J."},{"key":"ref_52","first-page":"e56025","article-title":"Ivermectin: A multifaceted drug with a potential beyond anti-parasitic therapy","volume":"16","author":"Kaur","year":"2024","journal-title":"Cureus"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.exppara.2009.10.013","article-title":"Fasciola gigantica: Parasitological and scanning electron microscopy study of the in vitro effects of ivermectin and\/or artemether","volume":"124","author":"Diab","year":"2010","journal-title":"Exp. Parasitol."},{"key":"ref_55","first-page":"58","article-title":"P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance","volume":"2","author":"Lespine","year":"2012","journal-title":"Int. J. Parasitol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Frigerio, S., Da Costa, V., Costa, M., Festari, M.F., Landeira, M., Rodr\u00edguez-Zraquia, S.A., H\u00e4rtel, S., Toledo, J., and Freire, T. (2020). Eosinophils control liver damage by modulating immune responses against Fasciola hepatica. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.579801"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.parint.2018.11.003","article-title":"Fasciola hepatica infection in children actively detected in a survey in rural areas of Mardan district, Khyber Pakhtunkhawa province, northern Pakistan","volume":"69","author":"Qureshi","year":"2019","journal-title":"Parasitol. Int."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/8\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:24:07Z","timestamp":1760034247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/8\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["tropicalmed10080221"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed10080221","relation":{},"ISSN":["2414-6366"],"issn-type":[{"type":"electronic","value":"2414-6366"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}